Neuroprotective and neurorestorative strategies for Parkinson's disease.
Advances in understanding the molecular mechanisms of cell death and the pathogenesis of sporadic and familial Parkinson's disease are creating new opportunities for the development of neuroprotective and/or neurorestorative therapies. Here we review many of these advances, highlighting areas and strategies that might be particularly suited to the development of innovative approaches that prevent degeneration and/or restore function in Parkinson's disease.
Dawson
Ted M
TM
Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA. tdawson@jhmi.edu
Dawson
Valina L
VL
D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D002135:Calcium-Binding Proteins; D004195:Disease Models, Animal; D015195:Drug Design; D006801:Humans; D008565:Membrane Proteins / Q000187:drug effects / Q000378:metabolism; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D009124:Muscle Proteins / Q000187:drug effects / Q000378:metabolism; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010300:Parkinson Disease / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology
D000978:Antiparkinson Agents; D002135:Calcium-Binding Proteins; D008565:Membrane Proteins; D009124:Muscle Proteins; D018696:Neuroprotective Agents; C091825:syntrophin alpha1